Course Experts: Allyson Beechy, PharmD

Course Description: This course defines the terminology associated with hastened death, the ethical conversations surrounding it, and the legal requirements for hastened death in states with active legislation.
Hastened Death, Medical Aid in Dying, Assisted Suicide, Euthanasia, Terminal Illness, Ethical Considerations, Legislation, Death with Dignity, Autonomy, Palliative Care, Prognosis, Oral Request, Written Re...

Course Experts: Joey Ricciutti, PharmD and Ben Kematick, PharmD, BCACP

Course Description: This course reviews the key events in the opioid epidemic and how those events impacted the perception of opioid use. For patients with advanced cancer, barriers, risks, and benefits of opioid use are discussed, as well as methods for assessing, monitoring, and treating their pain.
Opioid Epidemic, Advanced Cancer, Pain Management, Opioid Access, Opioid Utilizat...

Course Experts: Jennifer Espiritu, PharmD, BCOP, CCRP

Course Description: This course reviews basic genomic principles relevant to oncology, interprets patient-specific genomic profiles, and discusses significance of select mutations and their potential as therapeutic targets.
Pharmacogenomics, Germline Mutations, Somatic Mutations, BRCA, Oncogenic Mutations, Gain of Function, Loss of Function, DNA Transcription, RNA Translation, Codons, Point Mutatio...

Course Experts: Houry Leblebjian, PharmD, BCOP and Omar Marzouk, PharmD

Course Description: This course describes recent recommendations for newly diagnosed myeloma and evaluates the role of approved treatment options in relapsed/refractory multiple myeloma.

Credits: CEUs will be granted for pharmacists in disease state management.
Myeloma, CRAB Criteria, Hypercalcemia, Extramedullary Plasmacytomas, Hyperviscosity, Hypogammaglobulinemia, Amyloidosis, NCCN...

Course Experts: Emily Messing, PharmD, BCPS and Andrew Stivers, PharmD

Course Description: This course reviews the roles and responsibilities of the medication safety officer and summarizes activities led by the medication safety officer to improve safety within an organization.

Course Experts: Emily Messing, PharmD, BCPS and Andrew Stivers, PharmD

Course Description: This course reviews the phases of the medication use system and their relevance to oncology care and the risk reduction strategies in place at Dana-Farber Cancer Institute that enhance safe medication use.

Course Experts: Merihan Raouf, PharmD

Course Description: This course reviews patient safety culture, the importance of measuring safety culture through safety culture surveys, and converting the survey results into actionable items.
Safety Culture, Surveys, Organizational Culture, Patient Safety, Teamwork, Communication, Just Culture, Reporting, AHRQ, Likert Scale, SAQ (Safety Attitudes Questionnaire), SOPS (Surveys on Patient Safety Culture), Debrie...

Course Experts: Maria Vecchiarelli Kimball, PharmD, BCOP and Gia Troisi, PharmD, BCOP

Course Description: This course provides an overview of chemotherapy, immunotherapy, and targeted therapy families of drugs that are commonly used in the treatment of small cell and non-small cell lung cancer. It identifies common treatment regimens, adverse effects, and unique toxicities pertinent to each agent or combination regimen.
Lung Cancer, Small Cell Lung Ca...

Course Experts: Andrew Stivers, PharmD

Course Description: This course identifies and defines medication system failures as well as compares and contrasts human error, at risk behavior, and reckless behavior. It explains how to apply just culture principles in your practice.
Just Culture, Patient Safety, Active Failure, Latent Condition, Systems Approach, Human Error, At-Risk Behavior, Reckless Behavior, Accountability, Punitive, Safety Science, Drift...

Course Experts: Shahrier Hossain, PharmD

Course Description: This course compares different treatment options for chronic thrombocytopenia, recommends a thrombopoietin agonist based on patient-specific factors, and identifies the role of fostamatinib in therapy.
Immune Thrombocytopenia (ITP), Thrombocytopenia, Fostamatinib, Splenectomy, Rituximab, TPO Receptor Agonists (TPO-RAs), Romiplostim, Eltrombopag, Avatrombopag, Pathophysiology, Autoantibodies...

Course Experts: Emily Messing, PharmD, BCPS

Course Description: This course reviews human factors and how human factors engineering can be used to improve patient safety in the oncology settings.

Course Experts: Shahrier Hossain, PharmD, BCOP; Ashka Patel, PharmD, BCOP; Charles Ni, PharmD, MPH, BCOP; Emily Tiao, PharmD, BCOP

Course Description: This course covers the workings of CAR-T therapy and bispecific antibodies, assessing major trials, efficacy, safety, and managing side effects like cytokine release syndrome and neurotoxicity associated with these treatments.